Chiral biaryl nitrogen-phosphorus ligand compound as well as synthesis method and application thereof

By developing a multichiral synthesizing method of biaryl nitrogen and phosphorus ligand, the problems of low reactivity and substrate limitation of Quinap derivatives in asymmetric catalytic reactions are solved, and the coupling in asymmetric three-components is achieved The high optical purity and stereoselectivity of the addition reaction of quinoline salts of hydroxyalkyne are significantly better than traditional Quinap ligands.

CN119039348APending Publication Date: 2024-11-29SHANDONG NORMAL UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411203776.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-30
Publication Date
2024-11-29

AI Technical Summary

Technical Problem

Quinap derivatives have low reaction activity in asymmetric catalytic reactions, great substrate limitations, and lack efficient synthesis methods, which limit the application of chiral ligands in catalytic reactions.

Method used

A class of multichronous biaryl nitrogen and phosphorus ligands were developed to prepare excellent stereoscopy by the hybridization reaction of isonitrile, aryl halide and alkaline compounds in organic solvents, combined with hydrolysis and esterification reactions. A compound with selective effect and is used in combination with a copper catalyst to improve the stereoselectivity of the catalytic reaction.

Benefits of technology

It realizes high optical purity and stereoselectivity in asymmetric three-component coupling reactions and alkynium addition reactions to quinoline salts, which is significantly better than traditional Quinap ligands, reduces the reaction cost and steps, and improves the catalytic efficiency. .

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119039348A_ABST
    Figure CN119039348A_ABST
Patent Text Reader

Abstract

The invention relates to a chiral biaryl nitrogen-phosphorus ligand compound as well as a synthesis method and application thereof, in a general formula I, R1 is selected from aryl, alkyl, alkoxy, halogen and hydrogen; r2 is selected from an acyl substituent # imgabs0 #; R6 is selected from an alkoxy group and a nitrogen heterocyclic group; r3 is selected from hydrogen, alkyl, phenyl and substituted phenyl; r4 is selected from halogen and hydrogen; r5 is selected from aryl, substituted aryl and alkoxy; in the general formulas II-III, R1 is selected from aryl, alkyl, alkoxy, halogen and hydrogen; r2 is selected from alkyl, trifluoromethanesulfonic acid and hydrogen; r3 is selected from hydrogen, alkyl, phenyl and substituted phenyl; r4 is selected from halogen and hydrogen; r5 is selected from aryl, substituted aryl and alkoxy; research finds that the ligand 9a serving as a chiral ligand for A3 coupling reaction is matched with cuprous bromide, so that the original defect that a terminal alkyne substrate is only limited to a substrate with a relatively large steric hindrance group can be well overcome; the reactivity of aromatic aldehyde is low, and the enantioselectivity control is poor; and the ligand 10b can be matched with cuprous bromide to catalyze enantioselective addition reaction of alkyne to quinoline salt. # imgabs1 #
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of organic synthetic chemistry, and specifically relates to a class of chiral biaryl nitrogen-phosphorus ligand compounds and a synthesis method and application thereof. Background Art

[0002] The information disclosed in the background of the invention is only intended to enhance the understanding of the overall background of the invention and should not be necessarily regarded as an acknowledgment or any form of suggestion that the information constitutes the prior art already known to a person skilled in the art.

[0003] Chiral ligands play an important role in regulating the reactivity and enantioselectivity of asymmetric catalytic reactions. Therefore, it is of great significance to develop efficient synthesis methods for chiral ligands. Quinap is a classic class of axially chiral biaryl nitrogen-phosphorus ligands designed and synthesized by the Brown team. Since its discovery in 1993, Quinap has become an important subclass of nitrogen-phosphorus ligands. The axially chiral biaryl skeleton is constructed by 1-chloroisoquinoline and (2-methoxynaphthalen-1-yl)boronic acid through a palladium-catalyzed Suzuki coupling reaction, and then a series of functional group transformations are performed to finally obtain racemic Quinap. Finally, the racemate is resolved by using a stoichiometric chiral palladium complex to finally obtain optically pure Quinap, which exhibits unique stereocontrol in several enantioselective reactions, such as hydroboration, allylation, cycloaddition, A 3 Coupling reaction, etc. There has also been some progress in obtaining optically pure Quinap methods, such as chiral sulfoxide-assisted strategy (Synlett 2007, 17, 2655-2658), palladium-catalyzed dynamic kinetic phosphorylation reaction (J. Am. Chem. Soc. 2013, 135, 16829-16832, ACS Catal. 2016, 6, 3955-3964, Adv. Synth. Catal. 2019, 361, 441-444) and catalytic enantioselective nitrogen oxidation (Angew. Chem. Int. Ed. 2023, 62, e202309272).

[0004] At present, Quinap derivatives have not been fully developed, which makes it very limited as a chiral ligand in some asymmetric catalytic reactions, showing characteristics such as low reaction activity and large substrate limitation. Therefore, the development of an efficient new method for the de novo synthesis of Quinap has attracted much attention. This type of synthetic strategy can conveniently construct a series of Quinap derivatives with diverse structures and substituents, which is of great significance for studying the relationship between the steric effect and electronic effect of this type of ligand in asymmetric catalytic reactions. Summary of the invention

[0005] In view of the needs of the prior art, the present invention aims to provide a class of chiral biaryl nitrogen-phosphorus ligand compounds and their synthesis methods and applications. The present invention proves that such multi-chiral biaryl nitrogen-phosphorus ligands (1) have excellent stereoselectivity in the asymmetric three-component coupling reaction of terminal alkynes, aldehydes and amines, which is significantly better than Quinap; (2) have excellent stereoselectivity in the copper-catalyzed enantioselective addition reaction of alkynes to quinoline salts, which is significantly better than Quinap.

[0006] Specifically, the present invention provides the following technical solutions:

[0007] In a first aspect of the present invention, a class of biaryl nitrogen phosphorus ligand compounds with axial chirality or pharmaceutically acceptable salts, solvates and hydrates thereof are provided, wherein the biaryl nitrogen phosphorus ligand compound has a structure shown in general formula I:

[0008]

[0009] Among them, R 1 is a substituent on the benzene ring of the parent structure isoquinoline, the number of which is one or two, R 1 is selected from the group consisting of aryl, alkyl, alkoxy, halogen and hydrogen;

[0010] R 2 Selected from acyl substituents R 6 is selected from alkoxy and nitrogen heterocyclic groups;

[0011] R 3 is selected from the group consisting of hydrogen, alkyl, phenyl and substituted phenyl;

[0012] R 4 is selected from halogen and hydrogen;

[0013] R 5 is selected from aryl, substituted aryl and alkoxy.

[0014] Preferably, the R 1 Selected from hydrogen, C 1 -C 3 Alkyl, C 1 -C 3 Alkoxy, halogen and phenyl.

[0015] Preferably, the R 1 When it is phenyl, R 1 It shares two carbon atoms with the benzene ring to form a fused ring.

[0016] Preferably, the R 1 When the number is two, R 1 Selected from C 1 -C 3 Alkyl or phenyl.

[0017] Preferably, the R 1 is selected from the group consisting of hydrogen, methyl, methoxy, fluorine, chlorine and bromine.

[0018] Preferably, the R 1 The substitution position is selected from the 5-position, 6-position, 7-position and 8-position on isoquinoline; R 1 When the number is one, the preferred positions are 5 and 7; 1 When the number is two, the preferred positions are 6th and 8th.

[0019] Preferably, the R 2 One selected from ethyl ester group, lactam, and heteroatom lactam.

[0020] Preferably, the R 3 Selected from hydrogen, phenyl, and phenyl substituted with at least one of methyl, methoxy, and halogen.

[0021] Preferably, the R 3 is selected from the group consisting of phenyl, 4-tolyl, 4-methoxyphenyl, 4-fluorophenyl, 4-chlorophenyl, 4-bromophenyl and hydrogen.

[0022] Preferably, the R 4 Selected from 6-bromo and hydrogen.

[0023] Preferably, the R 5 Selected from C 1 -C 3 Alkoxy, phenyl, substituted phenyl and naphthyl, wherein the substituted phenyl is selected from C 1 -C 4 Alkyl, C 1 -C 3 The alkyl group is substituted by at least one of alkoxy and halogen; the preferred substitution positions are 3, 4 and 5; wherein, when there is one substituent, the preferred substitution position is 4; when there are two substituents, the preferred substitution positions are 3 and 5;

[0024] Preferably, the R 5 Selected from ethoxy, phenyl, naphthyl, methylphenyl, methoxyphenyl, tert-butylphenyl, chlorophenyl.

[0025] Preferably, the R 6 Selected from C 1 -C 3 Alkoxy and five- to seven-membered nitrogen heterocyclic groups.

[0026] Preferably, the R 6 It is selected from ethoxy, piperidinyl, pyrrolidinyl, azepanyl, morpholinyl, thiomorpholinyl, wherein the carbonyl group is connected with oxygen and nitrogen.

[0027] Preferably, the pharmaceutically acceptable salt is a derivative after group modification aimed at improving the physicochemical properties of the chiral biaryl nitrogen phosphorus ligand, usually a salt formed by the chiral biaryl nitrogen phosphorus ligand and an inorganic salt such as hydrochloric acid, sulfuric acid, nitric acid or hydrobromic acid, and a salt formed with an organic acid such as methanesulfonic acid, toluenesulfonic acid, citric acid or trifluoroacetic acid.

[0028] Preferably, the compound represented by general formula I comprises the following structure:

[0029]

[0030] The second aspect of the present invention provides a method for preparing the chiral biaryl nitrogen phosphorus ligand compound described in the first aspect, comprising the following steps:

[0031] S1, mixing an isonitrile, an aryl halide, a basic compound and a catalyst in an organic solvent to carry out a heterocyclization reaction;

[0032] S2. After the reaction, the organic solvent is removed and the compound represented by the general formula I is obtained after purification.

[0033] Preferably, in step S1, the molar ratio of the isonitrile to the aryl halide is 1:1.5 to 1:2.

[0034] Preferably, in step S1, the isonitrile is The aryl halide is

[0035] Preferably, in step S1, the alkaline compound is selected from one or more of cesium carbonate, cesium pivalate, potassium carbonate, and sodium carbonate; further preferably, the alkaline compound is cesium carbonate.

[0036] Preferably, in step S1, the molar ratio of the basic compound to the isonitrile is 1 to 1.5:1; further preferably, the molar ratio of the basic compound to the isonitrile is 1.2:1.

[0037] Preferably, in step S1, the organic solvent is selected from one or more of toluene, chlorobenzene, xylene, and 1,4-dioxane; further preferably, the organic solvent is toluene.

[0038] Preferably, in step S1, the catalyst is selected from one or more of palladium acetate and triphenylphosphine; further preferably, the catalyst is a mixture of palladium acetate and triphenylphosphine in a molar ratio of 1:2;

[0039] Preferably, in step S1, the reaction temperature of the heterocyclization reaction is 70-85°C, and the reaction time is 2-3.5 hours; further preferably, the reaction temperature of the heterocyclization reaction is 80°C, and the reaction time is 3 hours.

[0040] Preferably, in step S2, the purification specifically comprises subjecting the mixture from which the organic solvent has been removed to sequential operations of extraction, drying, filtration, concentration and silica gel column chromatography.

[0041] The third aspect of the present invention provides a class of biaryl nitrogen-phosphorus ligand compounds with multichirality or pharmaceutically acceptable salts, solvates and hydrates thereof, wherein the compound has a structure shown in general formula II or III:

[0042]

[0043] Among them, R 1 is selected from the group consisting of aryl, alkyl, alkoxy, halogen and hydrogen;

[0044] R 2 is selected from the group consisting of alkyl, triflate and hydrogen;

[0045] R 3 is selected from hydrogen, alkyl, phenyl and substituted phenyl, wherein the substituted phenyl is selected from phenyl substituted by at least one of halogen and alkoxy;

[0046] R 4 is selected from halogen and hydrogen;

[0047] R 5 is selected from aryl, substituted aryl and alkoxy;

[0048] The halogen is preferably fluorine, chlorine or bromine; the alkyl is preferably C 1 -C 3 Alkyl; the alkoxy group is preferably C 1 -C 3 Alkoxy; the aryl group is preferably phenyl.

[0049] Preferably, when the R 1 is 7-methyl, R 3 is 4-tolyl, R 4 is hydrogen, R 5 When it is phenyl, the R 2 One selected from hydrogen, methyl, isopropyl and trifluoromethanesulfonyl.

[0050] Preferably, the pharmaceutically acceptable salt is a derivative after group modification aimed at improving the physicochemical properties of the chiral biaryl nitrogen phosphorus ligand, usually a salt formed by the chiral biaryl nitrogen phosphorus ligand and an inorganic salt such as hydrochloric acid, sulfuric acid, nitric acid or hydrobromic acid, and a salt formed with an organic acid such as methanesulfonic acid, toluenesulfonic acid, citric acid or trifluoroacetic acid.

[0051] Preferably, the compounds represented by general formula II and III include the following structures:

[0052]

[0053] The fourth aspect of the present invention provides a method for preparing the chiral biaryl nitrogen phosphorus ligand compound according to the third aspect, comprising the following steps:

[0054] S1, mixing the compound represented by general formula I with sodium hydroxide in a solvent for hydrolysis reaction to obtain an acid;

[0055] S2, mixing the acid obtained in step S1, (S)-BINOL, EDCI and 4-dimethylaminopyridine in an organic solvent for esterification reaction to obtain SS-configuration phenolic ester and RS-configuration phenolic ester;

[0056] S3, dissolving the SS-configuration phenolic ester, triethylamine and trichlorosilane in an organic solvent for reduction reaction to obtain a compound represented by general formula II;

[0057] S4. Dissolve the RS-configured phenolic ester, triethylamine and trichlorosilane in an organic solvent for reduction reaction to obtain a compound represented by the general formula III.

[0058] Preferably, in step S1, the molar ratio of the compound represented by general formula I to sodium hydroxide is 1:3-15; further preferably, the molar ratio of the compound represented by general formula I to sodium hydroxide is 1:10.

[0059] Preferably, in step S1, the solvent is selected from one or more of ethanol and methanol; further preferably, the solvent is a mixture of ethanol and water in a volume ratio of 1:1.

[0060] Preferably, in step S1, the temperature of the hydrolysis reaction is 65-85°C, and the time is 8-15 hours; further preferably, the temperature of the hydrolysis reaction is 80°C, and the time is 10 hours.

[0061] Preferably, in step S1, after the hydrolysis reaction is completed, the diluted reaction solution is first adjusted to a pH of 2 using a hydrochloric acid solution, and then filtered, washed, and dried in sequence; wherein the filtered precipitate is washed with a mixed washing solution of ethanol and water in a volume ratio of 1:3.

[0062] Preferably, in step S2, the molar ratio of the acid obtained in step S1, (S)-BINOL, EDCI and 4-dimethylaminopyridine is 1:1.05:2:2.

[0063] Preferably, in step S2, the organic solvent is dichloromethane.

[0064] Preferably, in step S2, the esterification reaction is carried out at room temperature for 10 to 15 hours; further preferably, the reaction time of the esterification reaction is 12 hours.

[0065] Preferably, in step S2, the mixture after the esterification reaction needs to be separated by silica gel column chromatography; further preferably, the eluent of the silica gel column chromatography is a petroleum ether / ethyl acetate elution system with a volume ratio of 1:2 to 2:1.

[0066] Preferably, in step S3, the molar ratio of the SS-configuration phenolic ester, triethylamine and trichlorosilane is 1:30:10.

[0067] Preferably, in step S4, the molar ratio of the RS-configured phenolic ester, triethylamine and trichlorosilane is 1:30:10.

[0068] Preferably, in steps S3 and S4, the organic solvent is toluene.

[0069] Preferably, in steps S3 and S4, the reaction temperature of the reduction reaction is 90-120° C., and the time is 8-15 h; further preferably, the reaction temperature of the reduction reaction is 110° C., and the time is 12 h.

[0070] Preferably, in steps S3 and S4, the mixture after the reduction reaction needs to be sequentially subjected to the operations of dilution, quenching, filtration, drying, concentration and silica gel column chromatography.

[0071] The fifth aspect of the present invention provides the use of the multi-chiral biaryl nitrogen-phosphorus ligand compound described in the third aspect as a catalyst ligand in an asymmetric catalytic reaction.

[0072] Preferably, the asymmetric catalytic reaction includes but is not limited to an asymmetric three-component coupling reaction (A 3 The asymmetric three-component coupling reaction is preferably an asymmetric three-component coupling reaction of a terminal alkyne, an aldehyde and an amine.

[0073] In some embodiments of the present invention, the multichiral biaryl nitrogen-phosphorus ligand compounds of the present invention are combined with cuprous bromide as chiral ligands in the catalytic system for asymmetric three-component coupling reactions of terminal alkynes, aldehydes and amines. This reaction requires high enantioselectivity, and the ligands provided by the present invention can significantly improve the optical purity of the product (ee value up to 98%).

[0074] In some embodiments of the present invention, the multichiral biaryl nitrogen-phosphorus ligand compound of the present invention is combined with a copper catalyst to catalyze the enantioselective addition reaction of alkynes to quinoline salts, which can effectively improve the stereoselectivity of the catalytic reaction and has a better effect than the traditional Quinap ligand.

[0075] Therefore, the multichiral biaryl nitrogen-phosphorus ligand compound described in the present invention plays a key role in regulating stereochemistry in the catalytic system, helping the catalyst to achieve a highly selective catalytic process.

[0076] The beneficial effects achieved by one or more of the above technical solutions of the present invention are as follows:

[0077] (1) The method for preparing the compound of formula I provided by the present invention is a de novo synthesis strategy, which breaks the limitation that the axial chiral biaryl skeleton can only be constructed through Suzuki coupling reaction in the past, and can realize the diversified synthesis of Quinap derivatives. Compared with the existing synthesis methods, the number of reaction steps in the synthesis process is reduced, and it has a certain step economy.

[0078] (2) The compounds represented by the general formula II and III provided by the present invention are a kind of multi-chiral biaryl nitrogen-phosphorus ligand. The original synthesis method of chiral Quinap with similar structure was invented by Brown's team. The process requires the use of stoichiometric chiral palladium complexes, which is too costly. The present invention can be split by chiral binaphthol derivatives to obtain two optically pure diastereomers at the same time, and the reaction cost is greatly reduced, which has high economic benefits.

[0079] (3) The compounds represented by general formula II and III provided by the present invention are a kind of multi-chiral biaryl nitrogen-phosphorus ligands. Studies have shown that the stereoselectivity in various asymmetric catalytic reactions is far superior to that of the similar ligand Quinap. BRIEF DESCRIPTION OF THE DRAWINGS

[0080] The accompanying drawings in the specification, which constitute a part of the present invention, are used to provide a further understanding of the present invention. The exemplary embodiments of the present invention and their descriptions are used to explain the present invention and do not constitute improper limitations on the present invention.

[0081] Figure 1 The nuclear magnetic resonance hydrogen spectrum (a), carbon spectrum (b) and phosphorus spectrum (c) of compound 3a prepared in the present invention;

[0082] Figure 2 The nuclear magnetic resonance hydrogen spectrum (a), carbon spectrum (b) and phosphorus spectrum (c) of compound 4a prepared in the present invention;

[0083] Figure 3 The nuclear magnetic resonance hydrogen spectrum (a), carbon spectrum (b) and phosphorus spectrum (c) of compound 7a prepared in the present invention;

[0084] Figure 4 The nuclear magnetic resonance hydrogen spectrum (a), carbon spectrum (b) and phosphorus spectrum (c) of compound 8a prepared in the present invention;

[0085] Figure 5The nuclear magnetic resonance hydrogen spectrum (a), carbon spectrum (b) and phosphorus spectrum (c) of compound 9a prepared in the present invention;

[0086] Figure 6 The nuclear magnetic resonance hydrogen spectrum (a), carbon spectrum (b) and phosphorus spectrum (c) of compound 10a prepared in the present invention;

[0087] Figure 7 The nuclear magnetic resonance hydrogen spectrum (a), carbon spectrum (b) and phosphorus spectrum (c) of compound 9b prepared in the present invention;

[0088] Figure 8 The nuclear magnetic resonance hydrogen spectrum (a), carbon spectrum (b) and phosphorus spectrum (c) of compound 10b prepared in the present invention;

[0089] Fig. 9 The nuclear magnetic resonance hydrogen spectrum (a), carbon spectrum (b) and phosphorus spectrum (c) of compound 9c prepared in the present invention;

[0090] Fig.10 The nuclear magnetic resonance hydrogen spectrum (a), carbon spectrum (b) and phosphorus spectrum (c) of compound 10c prepared in the present invention;

[0091] Fig.11 The nuclear magnetic resonance hydrogen spectrum (a), carbon spectrum (b), phosphorus spectrum (c) and fluorine spectrum (d) of compound 10d prepared in the present invention;

[0092] Fig.12 Asymmetric A with 9a as ligand 3 HPLC chromatogram of reaction product 5a;

[0093] Fig.13 HPLC chromatogram of the enantioselective synthesis of propargylamine product 6a using 10b as a ligand. DETAILED DESCRIPTION

[0094] It should be noted that the following detailed descriptions are exemplary and are intended to provide further explanation of the present invention. Unless otherwise specified, all technical and scientific terms used herein have the same meanings as those commonly understood by those skilled in the art to which the present invention belongs.

[0095] In order to enable those skilled in the art to more clearly understand the technical solution of the present invention, the technical solution of the present invention will be described in detail below in conjunction with specific embodiments.

[0096] Source of reagents: The purity and origin of the experimental reagents used in the present invention and the model and origin of the experimental instruments are shown in Table 1 and Table 2, respectively.

[0097] Table 1 Experimental instruments

[0098] name model Origin Rotary evaporator YRE-5299 Gongyi Yuhua Instrument Co., Ltd. Low temperature coolant circulation pump DLSB-5L / 20 Gongyi Yuhua Instrument Co., Ltd. Circulating water multi-purpose vacuum pump SHZ-D(III) Gongyi Yuhua Instrument Co., Ltd. Electric constant temperature air drying oven DHG-9140A Gongyi Yuhua Instrument Co., Ltd. Magnetic heating stirrer MR Hei-Tec Shanghai Bajiu Industrial Co., Ltd. Dark box UV analyzer ZF-20D Gongyi Yuhua Instrument Co., Ltd. CNC ultrasonic cleaner KQ3200DE Kunshan Ultrasonic Instrument Co., Ltd. Electronic balance FA2004B Shanghai Tianmei Balance Instrument Co., Ltd. Vacuum drying oven DZF-6020 Shanghai Boxun Industrial Co., Ltd. Nuclear Magnetic Resonance Spectrometer BrukerDRX400 Bruker Technologies Ltd. High performance liquid chromatography G71269A Agilent Technologies

[0099] Table 2 Experimental drugs and reagents

[0100]

[0101]

[0102]

[0103]

[0104] In the following examples, the meanings of the abbreviations are as follows: CDCl 3 : deuterated chloroform; 1 H NMR: hydrogen nuclear magnetic resonance; 13 C NMR: carbon nuclear magnetic resonance; 31 P NMR: phosphorus nuclear magnetic resonance; 19 F NMR: fluorine nuclear magnetic resonance; HRMS(ESI): high resolution mass spectrometry (electrospray ionization); EDCI: 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride; (S)-BINOL: S-1,1'-bino-2-naphthol; DIPEA: N,N-diisopropylethylamine; [α] 33 D: optical rotation of the compound at 33°C; HPLC: high performance liquid chromatography; PE: petroleum ether; EA: ethyl acetate.

[0105] Synthesis of 1a-1p' :

[0106] From the easily available ethyl isocyanoacetate and aromatic aldehyde or aromatic ketone as starting materials, condensation, formylation and further dehydration are carried out to obtain a series of products. The reaction equation is shown in the figure:

[0107]

[0108] A series of reactions were performed on substrates with different substituents to obtain compounds 1a-1p', and a total of 17 compounds were obtained, all of which have been reported;

[0109] Synthesis of 2q-2y :

[0110] The first step: triflation reaction:

[0111]

[0112] Step 2: Phosphorylation reaction

[0113]

[0114] Through the above two-step transformation, substrates with different substituents were selected for a series of reactions to synthesize 2q-2y, and a total of 9 compounds were obtained, all of which have been reported.

[0115] Example 1 This example provides a preparation process of the compound of formula I

[0116]

[0117] In a flask equipped with a magnetic stirrer and a rubber stopper, compound 2, Pd(OAc) 2 PPh 3 , Cs 2 CO 3 and toluene. The system was quickly sealed, replaced with nitrogen three times, and stirred at 80°C for 5 minutes. Compound 1 was dissolved in toluene and added to the system via a syringe pump within 3 to 5 hours. The mixture was then cooled to room temperature, the reaction system was concentrated, diluted with ethyl acetate, and then transferred to a separatory funnel and extracted with saturated brine and ethyl acetate. The combined organic phase was dried over anhydrous sodium sulfate, concentrated under reduced pressure, and purified by column chromatography (PE:EA=1:1~1:3) to obtain compound 3 as a white solid.

[0118] The substrates with different substituents were selected for reaction to obtain a series of compounds 3, and a total of 26 compounds 3 (3a-3y) were obtained, with a reaction yield ranging from 31% to 98%. Among them, compounds 3b-3y were reacted on a scale of 0.5 mmol of raw material 1.

[0119] Example 2 :This example provides the preparation process and verification data of compound 3a

[0120]

[0121] In a 500 mL flask equipped with a magnetic stirrer and a rubber stopper, 2a (15 mmol), Pd(OAc) 2 (224 mg, 1.0 mmol), PPh 3 (524 mg, 2.0 mmol), Cs 2 CO 3(3.91g, 12mmol), toluene (200mL). The system was quickly sealed, replaced with nitrogen three times, and stirred at 80°C for 5min. 1a (10mmol) was dissolved in 200mL toluene and added to the system through a syringe pump within 5h. The mixture was then cooled to room temperature, the reaction system was concentrated, diluted with ethyl acetate (200mL), and then transferred to a 1000mL separatory funnel and extracted three times with saturated brine (200mL) and ethyl acetate (200mL). The combined organic phase was dried over anhydrous sodium sulfate and then concentrated under reduced pressure. Purification was performed by column chromatography (PE:EA=1:1~1:3) to obtain a white solid compound 3a (6.06g, yield 96%, melting point: 254-256°C). 1 H NMR (400 MHz, CDCl 3 )δ8.35(dd,J=11.0,8.7Hz,1H),8.17–8.05(m,3H),7.96(d,J=8.2Hz,1H),7.57 –7.43(m,4H),7.40(d,J=8.6Hz,1H),7.36–7.25(m,6H),7.10–7.05(m,2H),7.0 2(s,1H),6.92(d,J=8.6Hz,1H),6.87(td,J=7.4,1.5Hz,1H),6.72(td,J=7.7,3 .0Hz,2H),4.09–4.02(m,2H),2.47(s,3H),2.27(s,3H),0.98(t,J=7.1Hz,3H). 13 C NMR (101 MHz, CDCl 3 )δ167.3,156.7(d,J C-P =5.1Hz),141.1,140.3(d,J C-P =10.1Hz),138.4,137.8,134.9(d,J C-P =3.0Hz),133.0,132.92(d,J C-P =10.1Hz),132.9,132.7(d,J C-P =2.0Hz),132.5,132.3(d,J C-P =105.0Hz),131.7(d,J C-P =3.0Hz),131.67(d,J C-P =105.0Hz),131.2(d,J C-P =10.1Hz),130.8(d,J C-P=101.0Hz),130.19,130.17,130.1,129.6,129.2,129.1,129.0(d,J C-P =8.1Hz),128.6(d,J C-P =9.1Hz),128.2(d,J C-P =13.1Hz),128.16,128.0,127.2(d,J C-P =15.2Hz),126.8(d,J C-P =12.1Hz),126.5,125.9,61.0,21.7,21.4,13.9. 31 P NMR (162 MHz, CDCl 3 )δ30.8.HRMS(ESI)calcd for C 42 H 34 NO 3 PNa[M+Na] + 654.2169, found 654.2167.

[0122] Example 3 : This example provides the preparation process of compound 4a

[0123]

[0124] A 250 mL dry flask equipped with a magnetic stirrer was charged with 3a (6.31 g, 10.0 mmol), sodium hydroxide (4.0 g, 100 mmol), ethanol / H 2 O=1 / 1(150mL). Stir at 80℃ for 10h, and cool to room temperature after the reaction is completed. Pour the reaction solution into a 1000mL beaker and adjust the pH to 2 with hydrochloric acid solution. Filter the precipitate and 2 O=1 / 3 (50 mL) was used for washing. The product was dried to obtain a light grey solid 4a (5.79 g, yield 96%). 1 H NMR (400 MHz, CDCl 3 )δ8.06(dd,J=8.7,2.3Hz,1H),8.00(d,J=8.3Hz,1H),7.74–7.59(m,4H),7.47–7.26(m,12H),7.17( s,1H),7.13–7.08(m,1H),7.6–7.04(m,1H),6.98(td,J=7.7,2.9Hz,2H),2.47(s,3H),2.31(s,3H). 13 C NMR (101 MHz, CDCl 3 )δ165.2,155.1(d,JC-P =5.1Hz),142.2(d,J C-P =8.1Hz),139.3,137.6,136.6,136.1,134.9(d,J C-P =2.0Hz),134.8,132.8,132.4,132.2(d,J C-P =11.1Hz),131.9(d,J C-P =108.1Hz),131.8(d,J C-P =10.1Hz),131.7(d,J C-P =2.0Hz),131.3(d,J C-P =104.0Hz),131.1(d,J C-P =3.0Hz),131.0(d,J C-P =102.0Hz),130.4(d,J C-P =10.1Hz),129.8,129.7,129.4(d,J C-P =13.1Hz),129.2(d,J C-P =13.1Hz),129.0,128.8(d,J C-P =5.1Hz),128.5,128.4,128.3,127.7(d,J C-P =12.1Hz),127.5,127.2(d,J C-P =14.1Hz),126.4,21.8,21.5. 31 P NMR (162 MHz, CDCl 3 )δ29.5.HRMS(ESI)calcd for C 40 H 30 NO 3 PNa[M+Na] + 626.1856, found 626.1845.

[0125] Example 4 :This example provides the preparation process of compounds 7a and 8a

[0126]

[0127] A 50 mL dry flask equipped with a magnetic stirrer was added with 4a (603.0 mg, 1.0 mmol), (S)-BINOL (300.4 mg, 1.05 mmol), EDCI (383.4 mg, 2.0 mmol), 4-dimethylaminopyridine (244.3 mg, 2.0 mmol) and dichloromethane (20 mL). The mixture was stirred at room temperature for 12 h. The reaction mixture was directly subjected to column chromatography on silica gel (PE / EA = 1 / 2 to 2 / 1) to obtain the desired product 7a as a white solid (400.8 mg, yield 46%). 1 H NMR (400 MHz, CDCl 3 )δ8.27(dd,J=11.0,8.7Hz,1H),8.19–8.10(m,3H),8.04(d,J=8.9Hz,1H),8.00(d,J=8.1Hz,1H),7.94(d,J=8.2Hz,1H),7.61–7.56( m,1H),7.55(d,J=8.9Hz,1H),7.52(d,J=8.8Hz,1H),7.50–7.44(m,2H),7.40(dd,J=7.9,1.8Hz,1H),7.30–7.27(m,2H),7.25–7.16( m,8H),7.14(dd,J=7.8,2.0Hz,1H),6.94(s,1H),6.91–6.87(m,1H),6.86–6.82(m,1H),6.82–6.78(m,1H),6.73(d,J=8.6Hz,1H),6. 69(dd,J=7.7,2.0Hz,1H),6.65–6.57(m,2H),6.54–6.50(m,1H),6.34(s,1H),6.01(td,J=7.8,3.0Hz,2H),2.49(s,3H),2.25(s,3H). 13 C NMR (101 MHz, CDCl 3 )δ166.1,156.4(d,J C-P =5.1Hz),152.7,148.1,140.0,139.9,138.9,138.7,137.8,134.7,134.3,133.6,133.4,133.0,132.7(d,J C-P =11.1Hz),132.5,132.46,132.2,132.0,131.8,131.2(d,J C-P =3.0Hz),131.0,130.9,130.87(d,J C-P= 105.0 Hz), 130.8, 130.3, 130.2, 129.9, 129.84 (d, J C-P = 104.0 Hz), 129.8 (d, J C-P = 4.0 Hz), 129.5 (d, J C-P = 11.1 Hz), 129.3 (d, J C-P = 11.1 Hz), 128.8, 128.7, 128.5, 128.4, 128.2, 128.0, 127.9, 127.6, 127.4, 127.1, 126.44, 126.4, 126.3 (d, J C-P = 10.1 Hz), 126.0 (d, J C-P = 10.1 Hz), 124.4, 124.1, 123.1, 121.8, 118.9, 114.4, 21.7, 21.5. 31 P NMR (162 MHz, CDCl 3 ) δ 30.1. HRMS (ESI) calcd for C 60 H 42 NO 4 PNa [M + Na] + 894.2744, found 894.2741.

[0128] White solid 8a (392 mg, yield 45%). 1 H NMR (400 MHz, CDCl 3 ) δ 8.16 (dd, J = 11.1, 8.6 Hz, 1H), 8.06 (dd, J = 8.8, 1.9 Hz, 1H), 8.01–7.92 (m, 3H), 7.90 (d, J = 8.1 Hz, 1H), 7.87 (d, J = 8.2 Hz, 1H), 7.72 (d, J = 8.1 Hz, 1H), 7.62 (d, J = 8.9 Hz, 1H), 7.50 (t, J = 7.5 Hz, 1H), 7.42–7.35 (m, 2H), 7.30–7.26 (m, 1H), 7.25–7.12 (m, 10H), 7.10–7.03 (m, 3H), 7.00 (d, J = 8.9 Hz, 1H), 6.93 (d, J = 8.4 Hz, 1H), 6.87 (s, 1H), 6.82 (d, J = 8.6 Hz, 1H), 6.74–6.67 (m, 1H), 6.45–6.39 (m, 1H), 6.36 (td, J = 7.7, 2.9 Hz, 2H), 6.25 (dd, J = 7.8, 2.0 Hz, 1H), 6.14 (s, 1H), 2.27 (s, 3H), 2.16 (s, 3H).13 C NMR (101 MHz, CDCl 3 )δ165.7,156.7(d,J C-P =5.1Hz),152.3,148.0,140.4(d,J C-P =10.1Hz),139.0,138.6,137.4,135.3,134.8(d,J C-P =2.0Hz),134.1,133.7,133.3,132.8,132.7,132.6,132.4,132.0,131.7(d,J C-P =107.1Hz),131.5(d,J C-P =3.0Hz),131.4(d,J C-P =105.0Hz),131.2(d,J C-P =11.1Hz),130.7(d,J C-P =103.0Hz),130.3(d,J C-P =3.0Hz),129.9,129.8,129.77,129.6,129.2(d,J C-P =11.1Hz),128.9,128.89,128.7,128.6,128.4(d,J C-P =9.1Hz),128.22,128.2,128.19,128.1,128.06,128.0,127.3(d,J C-P =12.1Hz),127.1,126.9,126.5,126.4,126.3(d,J C-P =10.0Hz),125.9,125.5,123.2,121.9,118.9,114.5,21.7,21.3. 31 P NMR (162 MHz, CDCl 3 )δ30.5.HRMS(ESI)calcdfor C 60 H 42 NO 4 PNa[M+Na] + 894.2744, found 894.2702.

[0129] Example 5 :This example provides the preparation process and verification data of compound 9a

[0130]

[0131] At 0°C, 7a (218 mg, 0.25 mmol), triethylamine (1.05 mL, 7.5 mmol), trichlorosilane (250 uL, 2.5 mmol) and toluene (7.5 mL) were added to a 50 mL dry flask. The reaction mixture was heated at 110°C for 12 h. After cooling to room temperature, the mixture was diluted with ethyl acetate and quenched with a small amount of saturated sodium bicarbonate. The resulting suspension was filtered through diatomaceous earth, dried over magnesium sulfate, and then concentrated under reduced pressure. Purification by silica gel column chromatography using PE / EA = 10 / 1 as eluent gave 9a as a white solid (173.2 mg, yield 81%, melting point: 271-273°C). [α] 33 D =124.0(c 1.00,CHCl 3 ). 1 H NMR (400 MHz, CDCl 3 )δ7.95–7.91(m,3H),7.88(d,J=8.2Hz,1H),7.64(d,J=8.5Hz,1H),7.55(td,J=8.6,8.0,2.5Hz,2H),7.47(dd,J=8.5,3.6Hz,1H),7.44–7. 39(m,2H),7.32–7.18(m,10H),7.16–7.03(m,10H),7.00–6.87(m,4H),6.77(dd,J=7.9,2.0Hz,1H),5.63(s,1H),2.40(s,3H),2.07(s,3H). 13 C NMR (101 MHz, CDCl 3 )δ165.8,158.6(d,J C-P =5.1Hz),152.0,148.2,143.0,142.7,138.82,138.8,137.4,137.35,137.2,136.8(d,J C-P =12.1Hz),135.6(d,J C-P =15.2Hz),134.8,134.1,133.8,133.65(d,J C-P =13.1Hz),133.6,133.57(d,J C-P =20.2Hz),132.9(d,J C-P =7.1Hz),132.6,132.58,132.1,130.12,129.9,129.8,129.78,129.6,129.0,128.95,128.9,128.8,128.4,128.2(d,J C-P =2.0Hz),128.17(d,JC-P =18.2Hz),128.0,127.97,127.7,126.9,126.8(d,J C-P =2.0Hz),126.75,126.7,126.5,126.4,126.2,125.9,125.2,123.3,123.2,122.3,118.9,114.9,21.6,21.4. 31 P NMR (162 MHz, CDCl 3 )δ-12.4.HRMS(ESI)calcd for C 60 H 42 NO 3 PNa[M+Na] + 878.2795, found878.2767.

[0132] Example 6 :This example provides the preparation process and verification data of compound 10a

[0133]

[0134] In a 50mL dry flask, 8a (218mg, 0.25mmol), triethylamine (1.05mL, 7.5mmol), trichlorosilane (250uL, 2.5mmol) and toluene (7.5mL) were added. The reaction mixture was heated at 110°C for 12h. After cooling to room temperature, the mixture was diluted with ethyl acetate and quenched with a small amount of saturated sodium bicarbonate. The resulting suspension was filtered through celite, dried over magnesium sulfate, and then concentrated under reduced pressure. Purification by silica gel column chromatography using PE / EA=10 / 1 as eluent gave 10a as a white solid (171.1mg, yield 80%, melting point: 266-268°C). [α] 33 D = -182.0 (c 1.00, CHCl 3 ). 1 H NMR (400 MHz, CDCl 3 )δ7.89(d,J=4.3Hz,1H),7.87–7.80(m,3H),7.62(d,J=8.5Hz,2H),7.46–7.41(m,3H),7.38(d,J=7.6Hz,1H),7.30–7.25(m,6H),7.23–7 .16(m,4H),7.15–7.03(m,10H),7.01(d,J=7.8Hz,1H),6.98–6.92(m,3H),6.89(d,J=7.9Hz,1H),5.46(s,1H),2.41(s,3H),2.03(s,3H).13 C NMR (101 MHz, CDCl 3 )δ166.1,158.7(d,J C-P =5.1Hz),152.1,148.6,143.2,142.9,139.0,138.3,137.6(d,J C-P =13.1Hz),137.4,137.1(d,J C-P =12.1Hz),135.7,135.5(d,J C-P =15.2Hz),134.0(d,J C-P =21.2Hz),133.9(d,J C-P =14.4Hz),133.62,133.6(d,J C-P =19.2Hz),133.59,132.9,132.8(d,J C-P =7.1Hz),132.6,132.1,130.2,130.1(d,J C-P =3.0Hz),129.9(d,J C-P =3.0Hz),129.8,129.4,129.1,128.9,128.8,128.5,128.4,128.36,128.3,128.2,128.15,128.1,127.9,127 .8,127.0,126.8,126.73,126.7,126.5,126.4,126.0,125.2,123.2,123.1,122.3,118.7,114.5,21.6,21.5. 31 PNMR (162MHz, CDCl 3 )δ-12.7.HRMS(ESI)calcd for C 60 H 42 NO 3 PNa[M+Na] + 878.2795, found 878.2761.

[0135] Example 7 :This example provides the preparation process of compounds 7b and 8b

[0136]

[0137] A 50 mL flask equipped with a magnetic stirrer was added with 4a (603.0 mg 1.0 mmol), (S)-MeBINOL (315.1 mg, 1.05 mmol), EDCI (383.4 mg, 2.0 mmol), 4-dimethylaminopyridine (244.3 mg, 2.0 mmol), and dichloromethane (20 mL). Stirred at room temperature for 12 h. The reaction mixture was directly subjected to column chromatography on silica gel (PE / EA=1 / 2 to 2 / 1) to obtain the desired product as a white solid (mixture 7b and 8b ratio of 1:1) (796.8 mg, yield 90%). The products 7b and 8b have the same polarity and cannot be separated by column chromatography, so the pure spectrum was not measured. The characterization data of the reduction product will be provided after the reduction reaction in Example 8.

[0138] Example 8 This example provides the preparation process and verification data of compounds 9b and 10b.

[0139]

[0140] The product obtained from Example 7 is a mixture of 7b and 8b in a ratio of 1:1, and the yields of the obtained reduction products 9b and 10b are calculated separately.

[0141] At 0°C, 7b (110.7 mg, 0.125 mmol), 8b (110.7 mg, 0.125 mmol), triethylamine (1.05 mL, 7.5 mmol), trichlorosilane (250 uL, 2.5 mmol) and toluene (7.5 mL) were added to a dry 50 mL flask. The reaction mixture was heated at 110°C for 12 h. After cooling to room temperature, the mixture was diluted with ethyl acetate and quenched with a small amount of saturated sodium bicarbonate. The resulting suspension was filtered through diatomaceous earth, dried over magnesium sulfate, and then concentrated under reduced pressure. The crude product was purified by silica gel column chromatography using PE / EA = 15 / 1 to 1 / 5 as eluent to obtain white solid 9b (72.8 mg, yield 67%, melting point: 233-235°C) and white solid 10b (78.2 mg, yield 72%, melting point: 230-232°C).

[0142] White solid 9b: [α] 33 D =134.0(c 1.00,CHCl 3 ). 1 H NMR (400 MHz, CDCl 3)δ7.94(dd,J=8.5,4.0Hz,2H),7.85(dd,J=8.6,5.7Hz,2H),7.67(d,J=8.2Hz,1H),7.55(t,J=7.5Hz,1H),7.57–7.49(m,2H),7.45(d,J=8.6Hz,1H),7.36–7.07(m,20H),6.99(d,J=8.5Hz,1H),6.97–6.90(m,2H),6.88(d,J=9.0Hz,1H),6.82(d,J=7.8Hz,1H),6.47(d,J=7.8Hz,1H),3.35(s,3H),2.37(s,3H),2.02(s,3H). 13 C NMR(101MHz,CDCl 3 )δ165.0,158.4(d,J C-P =6.1Hz),155.4,147.4,144.2,143.8,139.6,138.5,137.6,137.4,137.3,137.2,135.1(d,J C-P =15.2Hz),134.1,134.0,133.8,133.79,133.7(d,J C-P =2.0Hz),133.5(d,J C-P =19.2Hz),132.9(d,J C-P =7.1Hz),132.8,132.4,131.8,130.3,129.8,129.7(d,J C-P =3.0Hz),129.5,129.4,129.0,128.7,128.6,128.5(d,J C-P =6.1Hz),128.3,128.26,128.24,128.2(d,J C-P =7.1Hz),128.1,128.0,127.8,127.1(d,J C-P =3.0Hz),126.9,126.6(d,J C-P =3.0Hz),126.4,126.3,126.2,125.8,125.2,125.1,123.2,122.3,117.5,114.0,56.6,21.6,21.4. 31 P NMR(162MHz,CDCl 3 )δ-13.9.HRMS(ESI)calcd for C 61 H 44 NO 3PNa[M+Na] + 892.2951, found 892.2928.

[0143] White solid 10b: [α] 33 D = -120.0 (c 1.00, CHCl 3 ). 1 H NMR (400 MHz, CDCl 3 ) δ 7.92 (dd, J = 8.3, 3.3 Hz, 2H), 7.85 (d, J = 9.4 Hz, 2H), 7.73 (d, J = 8.1 Hz, 1H), 7.67 (d, J = 9.0 Hz, 1H), 7.54–7.46 (m, 2H), 7.40–7.34 (m, 3H), 7.32–7.27 (m, 3H), 7.25–7.19 (m, 5H), 7.19–7.09 (m, 6H), 7.09–6.98 (m, 7H), 6.87 (s, 1H), 6.52 (d, J = 7.8 Hz, 1H), 6.45 (d, J = 7.7 Hz, 1H), 3.44 (s, 3H), 2.30 (s, 3H), 2.04 (s, 3H). 13 C NMR (101 MHz, CDCl 3 ) δ 165.4, 158.5 (d, J C-P = 5.1 Hz), 155.4, 147.3, 143.5, 143.2, 139.8, 138.4, 137.9 (d, J C-P = 13.1 Hz), 137.0, 136.9 (d, J C-P = 13.1 Hz), 135.2, 135.1, 134.3, 134.2 (d, J C-P = 21.2 Hz), 133.9 (d, J C-P = 10.1 Hz), 133.6, 133.2 (d, J C-P = 19.2 Hz), 133.0, 132.9, 132.4, 131.7, 130.1, 129.7, 129.66, 129.6, 129.5, 129.4, 128.9, 128.7, 128.6, 128.5, 128.3 (d, J C-P = 5.1 Hz), 128.1, 128.05, 128.0, 127.9, 127.8, 127.0 (d, J C-P = 3.0 Hz), 126.9, 126.6 (d, J C-P=4.0Hz),126.55,126.4,126.3,126.1,125.9,125.2,124.7,123.2,122.2,117.6,114.1,56.8(d,J C-P =3.0Hz),21.54,21.32. 31 PNMR (162MHz, CDCl 3 )δ-12.7.HRMS(ESI)calcd for C 61 H 44 NO 3 PNa[M+Na] + 892.2951, found892.2919.

[0144] Example 9 :This example provides the preparation process of compounds 7c and 8c

[0145]

[0146] A dry 50 mL flask equipped with a magnetic stirrer was added with 4a (603.0 mg 1.0 mmol), (S)-i-PrBINOL (345 mg 1.05 mmol), EDCI (383.4 mg 2.0 mmol) 4-dimethylaminopyridine (244.3 mg 2.0 mmol) and dichloromethane (20 mL). Stir at room temperature for 12 h. The reaction mixture was directly subjected to column chromatography on silica gel (PE / EA = 1 / 2 to 2 / 1) to obtain the desired product as a white solid (mixture 7c and 8c ratio 1:1) (785.4 mg, yield 86%). The products 7c and 8c have the same polarity and cannot be separated by column chromatography, so the pure spectrum was not measured, and the characterization data of the reduction product will be provided after the reduction reaction in Example 10.

[0147] Example 10 :This example provides the preparation process and verification data of compounds 7c and 8c

[0148]

[0149] The product obtained from Example 8 is a mixture of 7c and 8c in a ratio of 1:1, and the yields of the obtained reduction products 9c and 10c are calculated separately.

[0150] At 0°C, 7c (114.2 mg, 0.125 mmol), 8c (114.2 mg, 0.125 mmol), triethylamine (1.05 mL, 7.5 mmol), trichlorosilane (250 uL, 2.5 mmol) and toluene (7.5 mL) were added to a dry 50 mL flask. The reaction mixture was heated at 110°C for 12 h. After cooling to room temperature, the mixture was diluted with ethyl acetate and quenched with a small amount of saturated sodium bicarbonate. The resulting suspension was filtered through diatomaceous earth, dried over magnesium sulfate, and then concentrated under reduced pressure. The crude product was purified by silica gel column chromatography with PE / EA = 15 / 1 to 1 / 5 to obtain white solid 9c (78.5 mg, yield 70%, melting point: 320-322°C) and white solid 10c (75.2 mg, yield 67%, melting point: 336-338°C).

[0151] White solid 9c: [α] 33 D =166.2(c 1.00,CHCl 3 ). 1 H NMR (400 MHz, CDCl 3 )δ7.89(d,J=8.4Hz,2H),7.82(dd,J=8.7,5.7Hz,2H),7.70(dd,J=14.5,8.5Hz,2 H),7.51(t,J=7.6Hz,1H),7.48–7.40(m,2H),7.33–7.10(m,20H),7.08–6.99(m,3 H),6.95(d,J=8.5Hz,1H),6.69(d,J=7.8Hz,1H),6.13(d,J=7.8Hz,1H),4.00–3.9 4(m,1H),2.33(s,3H),2.05(s,3H),0.70(d,J=6.1Hz,3H),0.61(d,J=6.1Hz,3H). 13 C NMR (101 MHz, CDCl 3 )δ164.9,158.3(d,J C-P =7.1Hz),154.5,147.5,144.2,143.9,138.9,138.8,137.5(d,J C-P =12.1Hz),137.4(d,J C-P =13.1Hz),137.0,135.3,135.2,134.1,134.08,133.9(d,J C-P= 20.2 Hz), 133.87, 133.6, 133.4, 133.0, 132.9, 132.86, 132.5, 131.7, 130.3, 129.7, 129.69, 129.3, 129.2 (d, J C-P = 3.0 Hz), 128.9, 128.7, 128.6, 128.32 (d, J C-P = 13.1 Hz), 128.31, 128.3 (d, J C-P = 21.2 Hz), 128.1, 128.0, 127.7, 127.1 (d, J C-P = 3.0 Hz), 126.8 (d, J C-P = 6.1 Hz), 126.6, 126.5, 126.4, 126.3, 126.1, 126.0, 125.5, 125.1, 123.4, 122.3, 119.4, 117.2, 72.8, 22.6, 22.2, 21.7, 21.5. 31 P NMR (162 MHz, CDCl 3 ) δ -13.3. HRMS (ESI) calcd for C 63 H 48 NO 3 PNa [M+Na] + 920.3264, found 960.3230.

[0152] White solid 10c: [α] 33 D = -150.0 (c 1.00, CHCl 3 ). 1 H NMR (400 MHz, CDCl 3 ) δ 7.90 (d, J = 8.6 Hz, 2H), 7.83 (d, J = 8.6 Hz, 2H), 7.63 (d, J = 8.1 Hz, 1H), 7.57 (d, J = 9.0 Hz, 1H), 7.50–7.48 (m, 2H), 7.38–7.31 (m, 3H), 7.26–7.14 (m, 11H), 7.12–6.96 (m, 10H), 6.84–6.76 (m 3H), 4.23–4.17 (m, 1H), 2.35 (s, 3H), 1.97 (s, 3H), 0.86 (d, J = 6.1 Hz, 3H), 0.80 (d, J = 6.1 Hz, 3H). 13 C NMR (101 MHz, CDCl 3 ) δ 165.4, 158.3 (d, J C-P=6.1Hz),153.9,147.5,143.4,143.1,140.0,138.2(d,J C-P =20.2Hz),138.0(d,J C-P =13.1Hz),136.9(d,J C-P =14.1Hz),135.4(d,J C-P =15.2Hz),134.3(d,J C-P =21.2Hz),134.2,133.8(d,J C-P =8.1Hz),133.7,133.6,133.5,133.3,133.1,133.0,132.97,132.3,131.5,130.0,1 29.8,129.62,129.6,129.3,129.0,128.9,128.6,128.5,128.49,128.3,128.26(d,J C-P =9.1Hz),128.1,128.0(d,J C-P =5.1Hz),127.9,127.6,127.0(d,J C-P =2.0Hz),126.8,126.6,126.5,126.47,126.1,125.9(d,J C-P =9.1Hz),125.2,125.1,123.3,122.2,119.7,117.3,71.7,22.5,22.1,21.5,21.4. 31 P NMR (162 MHz, CDCl 3 )δ-12.3.HRMS(ESI)calcd for C 63 H 48 NO 3 PNa[M+Na] + 920.3264, found 960.3238.

[0153] Embodiment 11 :This example provides the preparation process and verification data of compound 10d

[0154]

[0155] 10a (85.5 mg, 0.1 mmol) and 4-dimethylaminopyridine (24.4 mg, 0.2 mmol) were added to a dichloromethane (1.5 mL) solution and stirred at 0°C for 10 min under nitrogen. Then trifluoromethanesulfonic anhydride (31 mg, 0.11 mmol) dissolved in 0.5 mL of dichloromethane was added via a syringe, and the mixture was stirred at 0°C for 5 h. The reaction mixture was directly subjected to column chromatography on silica gel (PE / EA=10 / 1) to obtain a white solid 10d (89.8 mg, yield 91%, melting point: 238-240°C). [α] 33 D = -140.0 (c 1.00, CHCl 3 ). 1 HNMR (400MHz, CDCl 3 )δ8.04–7.92(m,3H),7.88(d,J=8.2Hz,1H),7.58(t,J=7.6Hz,2H),7.47(d,J=8.7Hz,1H),7.46–7.39(m,2 H),7.36–7.28(m,6H),7.26–7.01(m,18H),6.88(s,1H),6.74(d,J=9.0Hz,1H),2.44(s,3H),1.96(s,3H). 13 C NMR (101 MHz, CDCl 3 )δ165.0,158.2(d,J C-P =6.1Hz),147.5,145.3,143.6,143.3,140.0,138.3,137.64(d,J C-P =12.1Hz),137.6,136.9(d,J C-P =13.1Hz),135.1,135.0,134.1(d,J C-P =21.2Hz),133.6,133.5,133.4,133.3,133.2,133.1,133.0,132.7,132.4,132.1,131.4,130.1,130.05,129.9(d,J C-P =4.0Hz),129.6(d,J C-P =3.0Hz),129.0(d,J C-P =7.1Hz),128.5,128.4,128.2,128.15,128.1,128.05,127.8(d,J C-P=9.1Hz),127.3,127.13,127.1,127.06,126.9,126.7,126.5,126.4,126.3(d,J C-P =4.0Hz),125.6,125.0,122.0,121.4,119.4,118.0,(q,J C-F =321.2Hz)21.43,21.4. 31 P NMR (162 MHz, CDCl 3 )δ-13.1. 19 F NMR (376 MHz, CDCl 3 )δ-74.6.HRMS(ESI)calcd for C 61 H 42 F 3 NO 5 PS[M+H] + 988.2468, found 988.2443.

[0156] Example 12 :This example provides 9a as a chiral ligand for the asymmetric synthesis of compound 5a

[0157]

[0158] A 15 mL flask flushed with dry nitrogen, equipped with a magnetic stirrer and a septum, was charged with cuprous bromide (3.6 mg, 0.025 mmol), 9a (25.7 mg, 0.03 mmol) and activated MS Molecular sieves (300 mg). The flask was sealed and replaced with nitrogen three times. Ultra-dry toluene (2 mL) was added and the mixture was stirred at room temperature for 45 min. Trimethylsilyl acetylene (0.5 mmol), cyclohexylcarboxaldehyde (0.5 mmol) and dibenzylamine (0.5 mmol) were dissolved in 1 mL of toluene and added to the flask using a syringe. The reaction mixture was stirred at room temperature for 4 d. After the reaction was completed, the reaction solution was diluted with n-hexane (10 mL), filtered, and washed with Et 2 O washing. Purification was performed using a silica gel column. A colorless transparent solid 5a (184.9 mg, 95%) was obtained. After desilylation of 5a, 98% ee was measured. [α] 33 D = -171.9 (c 1.00, CHCl 3 ). 1 H NMR (400 MHz, CDCl 3)δ7.29(d,J=6.9Hz,4H),7.24–7.16(m,4H),7.15–7.09(m,2H),3.70(d,J=13.8Hz,2H),3.25(d,J=13.7Hz,2H),2.93(d,J=10.4 Hz,1H),2.17(d,J=13.6Hz,1H),1.88(d,J=11.3Hz,1H),1.63–1.42(m,4H),1.15–0.88(m,3H),0.78–0.50(m,2H),0.15(s,9H). 13 C NMR (101 MHz, CDCl 3 )δ139.4,128.4,127.7,126.3,103.0,89.6,58.1,54.4,39.0,30.7,29.8,26.1,25.7,25.5,0.0.

[0159] Embodiment 13 This example provides 9a as a chiral ligand for the asymmetric synthesis of compounds 5b-5q

[0160] Compounds 5b-5q of the same series were prepared on a 0.5 mmol scale and under the same conditions (reaction time of aromatic aldehyde substrate extended to 6 d) and post-treatment methods to obtain the following Table 1 (wherein the enantioselectivity results of 9a as a ligand and Quinap as a ligand were compared):

[0161] Table 1

[0162]

[0163]

[0164] As can be seen from Table 1, the novel axial chiral nitrogen-phosphorus ligand 9a synthesized in the present invention and the catalytic system of cuprous bromide can play a very excellent role in the asymmetric three-component coupling reaction of terminal alkynes, aldehydes and amines. The ee value of the synthesized chiral propargyl amine product is as high as 98%. In particular, in the case of aromatic aldehyde substrates, the problem of poor enantioselectivity when Quinap is used as a ligand is solved. The ee value of the improved results reaches 90% or above in most examples, and the improvement in some examples is more than three times (5b-5q).

[0165] Embodiment 14 This example provides 10b as a chiral ligand for the asymmetric synthesis of compound 6a.

[0166]

[0167] A dry and nitrogen flushed 15 mL flask equipped with a magnetic stirrer and a septum was charged with cuprous bromide (1.8 mg, 0.0125 mmol), 10b (13.1 mg, 0.015 mmol). The flask was sealed and replaced with nitrogen three times. Dichloromethane (1 mL) was added and stirred at room temperature for 45 min. The mixture was then cooled to -20 °C and phenylacetylene (0.25 mmol) was added. Dissolved with 0.5 mL of dichloromethane, added to the flask with a syringe and stirred for 10 min. During this stirring time, in a separate flask of isobutyl chloroformate (0.25 mmol). Quinoline (0.25 mmol) (dissolved in 1.0 mL of dichloromethane) was added and stirred at room temperature for 10 min. The quinoline salt thus formed was transferred to the flask containing the copper catalyst and the alkyne, and DIPEA (0.35 mmol) dissolved in 0.5 mL of dichloromethane was then added via a syringe. The reaction mixture was stirred at -20 °C for 24 h, and the reaction mixture was directly subjected to column chromatography on silica gel (PE / EA) to obtain a white solid 6a (58.8 mg, yield 71%), with 92% ee measured by OD-H chiral column. [α] 33 D = -617.6 (c 1.00, CHCl 3 ). 1 H NMR (400 MHz, CDCl 3 )δ7.62(s,1H),7.24–7.16(m,3H),7.19–7.07(m,5H),7.08–6.93(m,2H),6.47(d,J=8.4 Hz,1H),6.07–5.94(m,2H),4.03–3.88(m,2H),2.01–1.84(m,1H),0.90(d,J=6.7Hz,6H). 13 C NMR (101 MHz, CDCl 3 )δ154.0,134.4,131.9,128.3,128.1,127.8,126.7,126.5,126.0,125.0,124.4,124.3,122.6,85.8,83.4,72.7,44.7,27.9,19.2.HRMS(ESI)calcd for C 22 H 21 NO 2 Na[M+Na] +354.1465,found 354.1457.Enantiomeric excess was determined by HPLC with aChiralcel OD-Hcolumn(90:10n-hexane:isopropanol,1.0mL / min,254nm); minor t r =5.29min; major t r =6.08min; 92%ee.

[0168] Embodiment 15 : Different from Example 14, this example provides the results of using 9a, 9b, 9c, 10a, 10c, and 10d as chiral ligands in the asymmetric synthesis of compound 6a.

[0169]

[0170] The test results show that 9a, 9b, 9c, 10a, 10c, and 10d as chiral ligands can play a certain stereoselective role in the asymmetric synthesis of compound 6a, among which 10d can reach an ee value of 90.6%. However, the overall effect comparison found that 10b is the best chiral ligand for this reaction.

[0171] Example 16 This example provides an asymmetric synthesis of compounds 6b-6i using 10b as a chiral ligand, which were obtained on a 0.25 mmol scale under the same reaction conditions and post-treatment method, as shown in Table 2 below (wherein, 10b is the substrate expansion result of the copper-catalyzed enantioselective addition reaction of alkynes to quinoline salts using the ligand):

[0172] Table 2

[0173] Entry <![CDATA[R 1 ]]> <![CDATA[R 2 ]]> <![CDATA[R 3 ]]> Yield(%) ee(%) 6a Ph H i-Bu 71 92 6b <![CDATA[2-NO 2 C 6 H 4 ]]> H i-Bu 63 90 6c <![CDATA[3,4-F 2 C 6 H 3 ]]> H i-Bu 52 91 6d <![CDATA[Ph(CH 2 ) 2 ]]> H i-Bu 40 92 6e Ph 6-MeO i-Bu 67 92 6f Ph 6-MeOCO i-Bu 55 91 6g Ph H i-Pr 56 90 6h Ph H n-Pr 67 90 6i Ph H Bn 41 89

[0174] As can be seen from Table 2, the novel axial chiral nitrogen-phosphorus ligand 10b synthesized in the present invention and the catalytic system of cuprous bromide can play a very excellent role in the enantioselective addition reaction of alkynes to quinoline salts, and the ee value of the product reaches 90% or more in most cases, which solves the problem of poor enantioselectivity when Quinap is used as a ligand. In the prior art, the literature reports that the ee value is only 42% when Quinap is used as a ligand, while the improved ligand 10b of the present invention has a significant improvement effect.

[0175] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. For those skilled in the art, the present invention may have various modifications and variations. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.

Claims

1. A class of biaryl nitrogen-phosphorus ligand compounds with axial chirality or pharmaceutically acceptable salts, solvates and hydrates thereof, It is characterized in that The biaryl nitrogen-phosphorus ligand compound has a structure shown in general formula I: Among them, R 1 is a substituent on the benzene ring of the parent structure isoquinoline, the number of which is one or two, R 1 is selected from the group consisting of aryl, alkyl, alkoxy, halogen and hydrogen; R 2 Selected from acyl substituents R 6 is selected from alkoxy and nitrogen heterocyclic groups; R 3 is selected from the group consisting of hydrogen, alkyl, phenyl and substituted phenyl; R 4 is selected from halogen and hydrogen; R 5 is selected from aryl, substituted aryl and alkoxy.

2. The biaryl nitrogen-phosphorus ligand compound having axial chirality according to claim 1 or a pharmaceutically acceptable salt, solvate or hydrate thereof, It is characterized in that The R 1 Selected from hydrogen, C 1 -C 3 Alkyl, C 1 -C 3 Alkoxy, halogen, and phenyl; Preferably, the R 1 When it is phenyl, R 1 It shares two carbon atoms with the benzene ring to form a fused ring; Preferably, the R 1 When the number is two, R 1 Selected from C 1 -C 3 Alkyl or phenyl; Preferably, the R 1 is selected from the group consisting of hydrogen, methyl, methoxy, fluorine, chlorine and bromine; Preferably, the R 1 The substitution position is selected from the 5-position, 6-position, 7-position and 8-position on isoquinoline; R 1 When the number is one, the preferred positions are 5 and 7; 1 When the number is two, the preferred positions are 6 and 8; Preferably, the R 2 One selected from ethyl ester group, lactam, and heteroatom lactam; Preferably, the R 6 Selected from C 1 -C 3 Alkoxy and five- to seven-membered nitrogen heterocyclic groups; Preferably, the R 6 Selected from ethoxy, piperidinyl, pyrrolidinyl, azepanyl, morpholinyl, thiomorpholinyl, wherein the carbonyl group is connected with oxygen and nitrogen; Preferably, the R 3 A phenyl group selected from hydrogen, a phenyl group, and a phenyl group substituted by at least one of a methyl group, a methoxy group, and a halogen group; Preferably, the R 3 is selected from the group consisting of phenyl, 4-tolyl, 4-methoxyphenyl, 4-fluorophenyl, 4-chlorophenyl, 4-bromophenyl and hydrogen; Preferably, the R 4 is selected from 6-bromo and hydrogen; Preferably, the R 5 Selected from C 1 -C 3 Alkoxy, phenyl, substituted phenyl and naphthyl, wherein the substituted phenyl is selected from C 1 -C 4 Alkyl, C 1 -C 3 The alkyl group is substituted by at least one of alkoxy and halogen; the preferred substitution positions are 3, 4 and 5; wherein, when there is one substituent, the preferred substitution position is 4; when there are two substituents, the preferred substitution positions are 3 and 5; Preferably, the R 5 Selected from ethoxy, phenyl, naphthyl, methylphenyl, methoxyphenyl, tert-butylphenyl, chlorophenyl.

3. The biaryl nitrogen-phosphorus ligand compound having axial chirality according to claim 1 or a pharmaceutically acceptable salt, solvate or hydrate thereof, It is characterized in that The compounds shown in general formula I include the following structures:

4. A method for preparing the biaryl nitrogen-phosphorus ligand compound having axial chirality or a pharmaceutically acceptable salt, solvate or hydrate thereof according to any one of claims 1 to 3, It is characterized in that The steps include: S1, mixing an isonitrile, an aryl halide, a basic compound and a catalyst in an organic solvent to carry out a heterocyclization reaction; S2. After the reaction, the organic solvent is removed and the compound represented by the general formula I is obtained after purification.

5. The preparation method according to claim 4, It is characterized in that In step S1, the molar ratio of the isonitrile to the aryl halide is 1:1.5 to 1:2; Preferably, the isonitrile is The aryl halide is Preferably, the alkaline compound is selected from one or more of cesium carbonate, cesium pivalate, potassium carbonate, and sodium carbonate; further preferably, the alkaline compound is cesium carbonate; Preferably, the molar ratio of the basic compound to the isonitrile is 1 to 1.5:1; further preferably, the molar ratio of the basic compound to the isonitrile is 1.2:1; Preferably, the organic solvent is selected from one or more of toluene, chlorobenzene, xylene, and 1,4-dioxane; further preferably, the organic solvent is toluene; Preferably, the catalyst is selected from one or more of palladium acetate and triphenylphosphine; further preferably, the catalyst is a mixture of palladium acetate and triphenylphosphine in a molar ratio of 1:2; Preferably, the reaction temperature of the heterocyclization reaction is 70-85°C, and the reaction time is 2-3.5h; further preferably, the reaction temperature of the heterocyclization reaction is 80°C, and the reaction time is 3h; Preferably, in step S2, the purification specifically comprises subjecting the mixture from which the organic solvent has been removed to sequential operations of extraction, drying, filtration, concentration and silica gel column chromatography.

6. A class of biaryl nitrogen-phosphorus ligand compounds having multichirality or pharmaceutically acceptable salts, solvates and hydrates thereof, It is characterized in that The compound has a structure shown in general formula II or III: Among them, R 1 is selected from the group consisting of aryl, alkyl, alkoxy, halogen and hydrogen; R 2 is selected from the group consisting of alkyl, triflate and hydrogen; R 3 is selected from hydrogen, alkyl, phenyl and substituted phenyl, wherein the substituted phenyl is selected from phenyl substituted by at least one of halogen and alkoxy; R 4 is selected from halogen and hydrogen; R 5 is selected from aryl, substituted aryl and alkoxy; The halogen is preferably fluorine, chlorine or bromine; the alkyl is preferably C 1 -C 3 Alkyl; the alkoxy group is preferably C 1 -C 3 Alkoxy; the aryl group is preferably phenyl; Preferably, when the R 1 is 7-methyl, R 3 is 4-tolyl, R 4 is hydrogen, R 5 When it is phenyl, the R 2 One selected from hydrogen, methyl, isopropyl and trifluoromethanesulfonyl.

7. The multichiral biaryl nitrogen-phosphorus ligand compound according to claim 6 or its pharmaceutically acceptable salt, solvate and hydrate, It is characterized in that The compounds shown in general formula II and III include the following structures:

8. A method for preparing the multichiral biaryl nitrogen-phosphorus ligand compound or its pharmaceutically acceptable salt, solvate and hydrate according to any one of claims 6 to 7, It is characterized in that The steps include: S1, mixing the compound represented by general formula I with sodium hydroxide in a solvent for hydrolysis reaction to obtain an acid; S2, mixing the acid obtained in step S1, (S)-BINOL, EDCI and 4-dimethylaminopyridine in an organic solvent for esterification reaction to obtain SS-configuration phenolic ester and RS-configuration phenolic ester; S3, dissolving the SS-configuration phenolic ester, triethylamine and trichlorosilane in an organic solvent for reduction reaction to obtain a compound represented by general formula II; S4. Dissolve the RS-configured phenolic ester, triethylamine and trichlorosilane in an organic solvent for reduction reaction to obtain a compound represented by the general formula III.

9. The preparation method according to claim 8, It is characterized in that In step S1, the molar ratio of the compound represented by general formula I to sodium hydroxide is 1:3-15; preferably, the molar ratio of the compound represented by general formula I to sodium hydroxide is 1:10; Preferably, the solvent is selected from one or more of ethanol and methanol; further preferably, the solvent is a mixture of ethanol and water in a volume ratio of 1:1; Preferably, the temperature of the hydrolysis reaction is 65-85°C and the time is 8-15h; further preferably, the temperature of the hydrolysis reaction is 80°C and the time is 10h; Preferably, after the hydrolysis reaction is completed, the diluted reaction solution is first adjusted to a pH of 2 using a hydrochloric acid solution, and then filtered, washed, and dried in sequence; wherein the filtered precipitate is washed with a mixed washing solution of ethanol and water in a volume ratio of 1:

3. Preferably, in step S2, the molar ratio of the acid obtained in step S1, (S)-BINOL, EDCI and 4-dimethylaminopyridine is 1:1.05:2:2; Preferably, the organic solvent is dichloromethane. Preferably, the esterification reaction is carried out at room temperature for 10 to 15 hours; further preferably, the reaction time of the esterification reaction is 12 hours; Preferably, the mixture after the esterification reaction needs to be separated by silica gel column chromatography; further preferably, the eluent of the silica gel column chromatography is a petroleum ether / ethyl acetate elution system with a volume ratio of 1:2 to 2:1; Preferably, in step S3, the molar ratio of the SS-configuration phenolic ester, triethylamine and trichlorosilane is 1:30:10; Preferably, in step S4, the molar ratio of the RS-configured phenolic ester, triethylamine and trichlorosilane is 1:30:10; Preferably, in steps S3 and S4, the organic solvent is toluene; Preferably, in steps S3 and S4, the reaction temperature of the reduction reaction is 90-120°C and the time is 8-15h; further preferably, the reaction temperature of the reduction reaction is 110°C and the time is 12h; Preferably, in steps S3 and S4, the mixture after the reduction reaction needs to be sequentially subjected to the operations of dilution, quenching, filtration, drying, concentration and silica gel column chromatography.

10. Use of the multichiral biaryl nitrogen-phosphorus ligand compound according to any one of claims 6 to 7 as a catalyst ligand in an asymmetric catalytic reaction; Preferably, the asymmetric catalytic reaction includes but is not limited to an asymmetric three-component coupling reaction and an addition reaction of an alkyne to a quinoline salt, and the asymmetric three-component coupling reaction is preferably an asymmetric three-component coupling reaction of a terminal alkyne, an aldehyde and an amine.